Weiss inquiry into OTC promethazine
Executive Summary
FDA has reportedly sent documents related to its approval of the Rx-to-OTC switch of promethazine (Wyeth-Ayerst's Phenergan) to the House Government Operations/Intergovernmental Relations Subcommittee in response to a request for information from subcommittee Chairman Weiss (D-N.Y.). Public Citizen's Health Research Group petitioned FDA to ban OTC sales of promethazine-based products because of reported association with sudden infant death syndrome. Weiss' group frequently follows up on allegations of drug safety problems. FDA's Pulmonary-Allergy Drugs Advisory Committee concluded at its July 31 meeting that promethazine's Rx-to-OTC switch should not be allowed by FDA ("The Pink Sheet" Aug. 7, p. 10). Reportedly, Wyeth-Ayerst's parent American Home Products sent a letter to FDA that sharply criticizes the committee's conclusions.
You may also be interested in...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.